CoreFirst Bank & Trust Purchases New Holdings in Stryker Co. (NYSE:SYK)

CoreFirst Bank & Trust purchased a new position in shares of Stryker Co. (NYSE:SYK - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 680 shares of the medical technology company's stock, valued at approximately $245,000.

Several other large investors have also added to or reduced their stakes in the company. J. W. Coons Advisors LLC grew its position in Stryker by 0.7% in the fourth quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock worth $1,315,000 after acquiring an additional 26 shares during the period. Mascoma Wealth Management LLC grew its holdings in shares of Stryker by 22.7% during the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock worth $53,000 after purchasing an additional 27 shares during the period. Opal Wealth Advisors LLC increased its position in shares of Stryker by 1.6% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after purchasing an additional 28 shares during the last quarter. Lindbrook Capital LLC lifted its position in Stryker by 2.0% in the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock valued at $507,000 after buying an additional 28 shares during the last quarter. Finally, Capital & Planning LLC boosted its stake in Stryker by 3.6% during the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company's stock worth $304,000 after buying an additional 29 shares during the period. Hedge funds and other institutional investors own 77.09% of the company's stock.

Remove Ads

Stryker Stock Down 0.9 %

Shares of Stryker stock traded down $3.16 during trading on Friday, hitting $364.38. 1,274,307 shares of the stock were exchanged, compared to its average volume of 1,289,456. The stock has a market cap of $139.08 billion, a price-to-earnings ratio of 46.96, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The firm's 50-day moving average price is $384.08 and its 200 day moving average price is $374.32. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the company posted $3.46 earnings per share. As a group, analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. Stryker's dividend payout ratio is presently 43.30%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on SYK. Truist Financial boosted their price target on shares of Stryker from $409.00 to $413.00 and gave the company a "hold" rating in a research note on Thursday, January 30th. Canaccord Genuity Group boosted their target price on Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. The Goldman Sachs Group set a $422.00 price target on Stryker in a research report on Tuesday, March 4th. Morgan Stanley raised Stryker from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. Finally, Stifel Nicolaus increased their target price on Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research note on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $421.90.

Insider Activity at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.